Flex Pharma Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2014
2015
2016
2017
2018
Cash & Short Term Investments
33,854.20
91,339.00
61,075.00
33,315.80
9,956.20
Total Accounts Receivable
-
-
12.20
10.40
9.90
Inventories
-
-
454.10
431.90
186.90
Other Current Assets
370.40
908.60
926.00
777.10
162.10
Total Current Assets
34,224.50
92,247.60
62,467.30
34,535.10
10,315.20
Net Property, Plant & Equipment
85.10
382.40
556.30
331.00
74.50
Total Investments and Advances
126.80
2,439.80
126.60
126.60
-
Other Assets
1,124.80
-
64.80
-
-
Total Assets
35,611.40
95,069.80
63,215.00
34,992.80
10,389.60
Accounts Payable
-
-
1,192.20
2,004.40
Income Tax Payable
50.10
-
-
-
Other Current Liabilities
1,017.10
2,847.40
2,697.00
3,843.20
Total Current Liabilities
1,067.20
2,847.40
3,889.20
5,847.70
Deferred Taxes
50.10
-
-
-
Other Liabilities
51.40
30.00
8.40
39.20
Total Liabilities
1,118.60
2,877.40
3,897.60
5,886.90
Common Equity (Total)
6,538.30
92,192.40
59,317.40
29,105.90
Total Shareholders' Equity
34,492.80
92,192.40
59,317.40
29,105.90
Total Equity
34,492.80
92,192.40
59,317.40
29,105.90
Liabilities & Shareholders' Equity
35,611.40
95,069.80
63,215.00
34,992.80
Preferred Stock (Carrying Value)
41,031.20
-
-
-

About Flex Pharma

View Profile
Address
31 St. James Avenue
Boston Massachusetts 02116
United States
Employees -
Website http://www.flex-pharma.com
Updated 07/08/2019
Flex Pharma, Inc. operates as a biotechnology company. It engages in developing treatments for exercise-associated muscle cramps, nocturnal leg cramps and spasms associated with severe neuromuscular conditions. The company operates through the following business segments: Consumer Operations and Drug Development.